Sana says NEJM publishes 14-month data supporting hypoimmune islet transplant in type 1 diabetes without immunosuppression
SANA•Next clinical step
Sana expects to file an IND and start a Phase 1/2 trial as early as this year for SC451, a stem cell-derived HIP-modified therapy.
Safety and imaging findings
No safety issues were identified, and imaging at 52 weeks showed islet cells at the forearm muscle transplant site.
NEJM publishes 14-month follow-up data
Sana Biotechnology highlighted NEJM publication of 14-month follow-up data for UP421 hypoimmune-modified islet cell transplant in type 1 diabetes.
The study reported continued insulin production without immunosuppression, with circulating C-peptide present at month 14 versus undetectable at baseline.
